# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*

**11-522/S-030**

# CHEMISTRY REVIEW(S)

# CHEMIST'S REVIEW OF SUPPLEMENT

| | |
|---|---|
| **ORGANIZATION:** | HFD-120 |
| **NDA NUMBER:** | **11-522** |
| **SUPPLEMENT NUMBER:** | **SCF-030** |
| LETTER DATE | 20-NOV-01 |
| STAMP DATE | 20-NOV-01 |
| **AMENDMENTS/REPORTS:** | |
| LETTER DATE | 08-JUL-01 |
| STAMP DATE | 08-JUL-01 |
| **RECEIVED BY CHEMIST:** | 28-OCT-02 |

**APPLICANT NAME AND ADDRESS:** Shire Laboratories
1901 Research Blvd., Suite 500
Rockville, MD 20850

**NAME OF DRUG:** **Adderall® CII**
**NONPROPRIETARY NAME:** Mixed salts of a single-entity amphetamine product
**CHEMICAL NAME / STRUCTURE:** Amphetamine sulfate USP
Amphetamine aspartate monohydrate
Dextroamphetamine sulfate USP
Dextroamphetamine saccharate



**Amphetamine**

**DOSAGE FORM(S):** Tablets
**POTENCY(IES):** 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg
**PHARMACOLOGICAL CATEGORY:** Treatment of ADHD
**HOW DISPENSED:** XX (Rx) ___ (OTC)
**RECORDS / REPORTS CURRENT:** XX (YES) ___ (NO)
**RELATED IND / NDA / DMF(S):** N/A

**SUPPLEMENT PROVIDES FOR:** an improved formulation of the current commercially available Adderall® for all seven strengths (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg) and for a new manufacturing site.

**COMMENTS:** In this response, the sponsor has provided a complete response to the AE letter date (20-MAR-02). There were no CMC issues in the AE letter (Dr. Christy John found the original supplement acceptable). In this submission, the sponsor has revised the manufacturing batch size for the 5 mg tablet from kg. All other tablet strengths batch sizes remain at kg. Shire has committed to perform complete validation on 9 Adderall blend batches: three batches of the white blend at kg (5 mg tablets), three batches of the blue blend at kg (7.5 mg and 10 mg), and three batches of the yellow blend at kg (12.5 mg, 15 mg, 20 mg, and 30 mg tablets). In a telecon with Ms. Debbie Aleknavage (Shire, 240-453-6446), I was informed that there were no changes to the components or composition of the tablets from the original supplement. The new DP manufacturing site was found acceptable 19-MAR-02 (based on profile). The last inspection was 30-AUG-01 (according to EER S-030). In an email to EES QUESTIONS, a final update was requested of the two sites submitted in the original supplement. Compliance responded that both sites are acceptable (05-NOV-02; Janine D Ambrogio).

**CONCLUSIONS AND RECOMMENDATIONS:** Recommend **APPROVAL**

| REVIEWER NAME | SIGNATURE | DATE COMPLETED |
|---|---|---|
| Thomas F. Oliver, Ph.D. | | November 5, 2002 |

cc: Orig. NDA 11-522/SCF-030
HFD-120/Div. File
HFD-120/TOliver
HFD-120/HPatel
INIT: HPatel

Filename: s11-522.030.response.AEletter

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Thomas Oliver
11/5/02 08:30:10 AM
CHEMIST

Hasmukh Patel
11/5/02 10:20:50 AM
CHEMIST

CHEMIST REVIEW
OF SUPPLEMENT

| | |
|---|---|
| 1. ORGANIZATION: | HFD-120 |
| 2. NDA: | 11-522 |
| 3. SUPPLEMENT NUMBERS/DATES: | SCF-030 |
| Letter date: | November 20, 2001 |
| Stamp date: | November 20, 2001 |
| 4. AMENDMENTS/REPORTS/DATES: | N/A |
| 5. RECEIVED BY CHEMIST: | November 24, 2001 |
| 6. APPLICANT NAME & ADDRESS | Shire Laboratories, Inc.<br>1901 Research Boulevard, Suite 500<br>Rockville, MD 20850 |
| 7. NAME OF DRUG: | ADDERALL CII (Mixed salts of a single-Entity Amphetamine Product) |
| 8. NONPROPRIETARY NAME: | (Code Name: SLI 371) |
| 9. CHEMICAL NAME/STRUCTURE: | Amphetamine sulfate USP, Amphetamine aspartate monohydrate, Dextroamphetamine sulfate USP, and Dextroamphetamine saccharate |
| 10. DOSAGE FORM(S): | Tablets |
| 11. POTENCY: | 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg. |
| 12. PHARMACOLOGICAL CATEGORY: | Treatment of ADHD |
| 13. HOW DISPENSED: | X ($R_X$) _____ (OTC) |
| 14. RECORDS & REPORTS CURRENT: | _____ Yes _____ No |
| 15. RELATED IND/NDA/DMF: | N/A |

**SUPPLEMENT PROVIDES FOR**: This supplement provides for seven strengths 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg of Tablets, which is an improved formulation of the commercially available ADDERALL Tablets. The changes to commercial ADDERALL Tablets are intended to improve the drug product stability and optimize the new manufacturing process at a new manufacturing site.

**Conclusion:** This supplement may be approved.

Reviewer's Signature

Christy S. John, Ph.D.

Acting Team Leader

Hasmukh Patel, Ph.D.

Redacted 19

pages of trade

secret and/or

confidential

commercial

information

Chem Review